The National Agency for Food and Drugs Administration and Control (NAFDAC) has issued a public alert (No. 034/2023) to inform the public that G Fuel brand Energy Drinks, distributed by T&E Imports and GPAE Trading Corp, have been recalled due to their high caffeine content. This notification was made by Prof Mojisola Adeyeye, the Director-General of NAFDAC, during a press release in Abuja on Thursday.
Adeyeye mentioned that NAFDAC was also informed about the recall of these products by both the Netherlands Food and Consumer Product Safety Authority and the Canadian Food Inspection Agency.
The Director-General of NAFDAC expressed concerns about the potential health risks associated with the consumption of products with elevated caffeine levels, including headaches, insomnia, irritability, and nervousness. She emphasized that even individuals sensitive to caffeine could experience these effects at very low consumption levels.
Furthermore, Adeyeye advised pregnant women against using these products, as excessive caffeine intake can lead to an increased risk of miscarriage and low birth weight.
Adeyeye also noted that the affected products lack proper cautionary statements regarding daily serving limits and are primarily available for purchase online. It’s important to highlight that these products have not been registered with NAFDAC, and consumers and retailers are urged to avoid using, selling, serving, or distributing them.
The public is encouraged to report any suspicious distribution or sale of such substandard packaged food products to the nearest NAFDAC office. NAFDAC can be reached via the phone number 0800-162-3322 or the email address sf.alert@nafdac.gov.ng.
Healthcare professionals and patients are also urged to report any adverse events or side effects related to the use of NAFDAC-regulated products to the nearest NAFDAC office or through the E-reporting platforms on the NAFDAC website (www.nafdac.gov.ng) or the Med-safety application available for download on Android and IOS stores. Additionally, NAFDAC can be contacted via email at pharmacovigilance@nafdac.gov.ng.
Disclaimer
The provided information is intended for general awareness and may not be entirely accurate or up-to-date. The post disclaims any warranties regarding the completeness, accuracy, or reliability of the content, services, or graphics on the website. It advises caution when using the information for any purpose.